Our mission is to help innovative projects grow. We invest in European Life Sciences companies focused on drug discoveries, medical devices, diagnostics and digital health. We specialize on cutting-edge ideas that have the potential to succeed on a global scale.
Dracen is completing the first phase of clinical testing of DRP-104 (sirpiglenastat), which has the potential to significantly help the treatment of cancer.
The company aims to develop a diagnostic device to provide patients with the flexibility to assess their coagulation status regardless of where they are.
Enzyre’s platform requires a small volume of blood to measure up to sixteen reactions simultaneously with high sensitivity and specificity without any laboratory infrastructure, at home, on the road or in a critical care setting. This offers enormous benefits to patients: avoid crisis situations driven by changes in coagulation status, provide ease of mind for patients, empower patients to optimize treatment themselves, be a quick turnaround tool in the clinical setting, reduce GP consultation visits and, as a personalized diagnostic tool, offer great support in a telemedicine setting.
Nanoligent is a biotech company specialized in the development of cancer treatments based on unique protein conjugates.
Nanoligent is focused on the development of new drugs for the treatment of more than 20 different metastatic cancer types. The lead molecule is based on the targeted elimination of cancer cells overexpressing the CXCR4 receptor, a recognized biomarker for poor prognosis and therapy resistance. Nanoligent is developing a new proprietary nano-technological platform, with the potential to overcome current limitations of Antibody-Drug-Conjugates.
CasInvent Pharma is an early-stage drug discovery company developing a proprietary small-molecule lead compounds with anticancer properties.
CasInvent Pharma is developing proprietary, highly selective inhibitors of enzymes belonging to the casein kinase 1 (CK1) family, which play an important role in several disease-related processes, including the migration of leukemia cells into lymphoid organs. The small-molecule inhibitors are designed to target individual isoforms of CK1 and thereby selectively eradicate leukemic cells.
Sampling Human is a life science technology company developing novel methods for the early detection of disease.
The company has developed simple and easy to perform diagnostic reagent kits for the liquid biopsy of healthy and diseased cells and a proprietary method of harnessing living cells to analyze other cells. The company engineers and manufactures accessible tools that elevate sensitivity and increase speed of assay well beyond performance limits of complex instruments such as flow cytometry.
Dracen is a private pharmaceutical company leveraging immuno-metabolism to create a potential new treatment paradigm with broad application for many cancer types.
Its goal in treating cancers is to directly shrink tumors and remodel the tumor microenvironment to make it more conducive to immuno-oncology approaches, to gain greater disease control, increase anti-tumor responses and extend patient survival in areas of unmet need.
The company designs medicines for currently incurable diseases by exploiting AI to build a novel and promising therapeutics class that induces targeted protein degradation (proximity-inducing compounds, short PICs™).
PICs™ induce proximity to cellular machinery and require a deep understanding of chemistry and biology. The company developed the Celeris® One™ platform to design such drugs rationally by predicting interactions and generating the fragments and whole compounds. The company runs multiple drug development programs in neurology and oncology while collaborating with big pharma companies in collaborations.